Print

Enanta Pharmaceuticals, Inc. Announces New Data on ABT-450 Regimens to be Presented at The Liver Meeting American Association for Study of Liver Diseases  
10/1/2013 10:55:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that six abstracts reporting results of regimens containing ABT-450, Enanta’s lead protease inhibitor for hepatitis C virus (HCV), have been accepted for presentation at The Liver Meeting, the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 1-5, 2013 in Washington, D.C. Abstracts can now be viewed at the AASLD website at www.aasld.org.

Help employers find you! Check out all the jobs and post your resume.

//-->